AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 12144575 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple therapy (omeprazole 20 mg, amoxicillin 1 g, clarithromycin 500 mg, all b.d.)
Number of subjects: 339
Study 12144575 — intervention group
Group type: EXPERIMENTAL
Intervention: Quadruple therapy (omeprazole 20 mg b.d., tetracycline chloride 500 mg, metronidazole 500 mg, bismuth subcitrate 120 mg, all t.d.s.)
Number of subjects: 339
Study 9447610 — intervention group
Group type: EXPERIMENTAL
Intervention: SMA III patients with disease duration of < or = 11 years
Number of subjects: 26
Study 9447610 — intervention group
Group type: EXPERIMENTAL
Intervention: SMA III patients with disease duration of > or = 16 years
Number of subjects: 26
Study 9447610 — intervention group
Group type: EXPERIMENTAL
Intervention: SMA III patients with disease onset at < or = 3 years of age
Number of subjects: 26
Study 9447610 — intervention group
Group type: COMPARATOR
Intervention: SMA III patients
Number of subjects: 26
Study 8188493 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief supportive telephone counseling (3 calls)
Number of subjects: 0
Study 3163501 — intervention group
Group type: EXPERIMENTAL
Intervention: Nalbuphine (0.2 mg/kg)
Number of subjects: 40
Study 3163501 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentazocine (0.5 mg/kg)
Number of subjects: 40
Study 3163501 — intervention group
Group type: COMPARATOR
Intervention: Midazolam alone (historical control)
Number of subjects: 40
Study 11684628 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin C treatment
Number of subjects: 0
Study 11684628 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 29671035 — intervention group
Group type: EXPERIMENTAL
Intervention: StO2 <75%
Number of subjects: 60
Study 29671035 — intervention group
Group type: COMPARATOR
Intervention: StO2 ≥75%
Number of subjects: 60
Study 29671035 — intervention group
Group type: EXPERIMENTAL
Intervention: StO2
Number of subjects: 60
Study 29311053 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 years of exercise training (n=34)
Number of subjects: 61
Study 29311053 — intervention group
Group type: COMPARATOR
Intervention: Attention control (n=27)
Number of subjects: 61
Study 26764065 — intervention group
Group type: EXPERIMENTAL
Intervention: CABG
Number of subjects: 220
Study 26764065 — intervention group
Group type: COMPARATOR
Intervention: PCI
Number of subjects: 220
Study 26764065 — intervention group
Group type: COMPARATOR
Intervention: PCI vs CABG
Number of subjects: 220
Study 24911432 — intervention group
Group type: EXPERIMENTAL
Intervention: Dabigatran 150 mg BID
Number of subjects: 70000
Study 24911432 — intervention group
Group type: EXPERIMENTAL
Intervention: Apixaban BID
Number of subjects: 70000
Study 24911432 — intervention group
Group type: EXPERIMENTAL
Intervention: BID dosing regimen
Number of subjects: 70000
Study 24911432 — intervention group
Group type: COMPARATOR
Intervention: BID dosing regimen vs rivaroxaban QD
Number of subjects: 70000
Study 24911432 — intervention group
Group type: COMPARATOR
Intervention: BID dosing regimen vs edoxaban QD
Number of subjects: 70000
Study 24911432 — intervention group
Group type: COMPARATOR
Intervention: Non-vitamin K antagonist oral anticoagulants vs warfarin
Number of subjects: 70000
Study 23654014 — intervention group
Group type: EXPERIMENTAL
Intervention: Early multimodal accelerated rehabilitation program (mean duration 7.24 days)
Number of subjects: 58
Study 20512336 — intervention group
Group type: EXPERIMENTAL
Intervention: Strontium ranelate 2 g/day
Number of subjects: 88
Study 20512336 — intervention group
Group type: COMPARATOR
Intervention: Alendronate 70 mg/week
Number of subjects: 88
Study 17085009 — intervention group
Group type: EXPERIMENTAL
Intervention: Music therapy
Number of subjects: 30
Study 17085009 — intervention group
Group type: COMPARATOR
Intervention: Uninterrupted rest
Number of subjects: 30
Study 15692829 — intervention group
Group type: EXPERIMENTAL
Intervention: Theophylline (6 mg kg (‐1) body weight) intravenously
Number of subjects: 20
Study 15692829 — intervention group
Group type: EXPERIMENTAL
Intervention: Verapamil (5 mg) intravenously
Number of subjects: 20
Study 15692829 — intervention group
Group type: EXPERIMENTAL
Intervention: 1,3-Dimethyluric acid
Number of subjects: 20
Study 15692829 — intervention group
Group type: EXPERIMENTAL
Intervention: Norverapamil
Number of subjects: 20
Study 11994030 — intervention group
Group type: EXPERIMENTAL
Intervention: Lansoprazole
Number of subjects: 10008
Study 10215747 — intervention group
Group type: EXPERIMENTAL
Intervention: Selegiline (5 mg, 10 mg, 20 mg, 40 mg) with oral contraceptives
Number of subjects: 8
Study 10215747 — intervention group
Group type: COMPARATOR
Intervention: Selegiline (5 mg, 10 mg, 20 mg, 40 mg) without oral contraceptives
Number of subjects: 8
Study 10215747 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral contraceptives
Number of subjects: 8
Study 10215747 — intervention group
Group type: EXPERIMENTAL
Intervention: Selegiline (5 mg, 10 mg, 20 mg, 40 mg)
Number of subjects: 8
Study 10215747 — intervention group
Group type: EXPERIMENTAL
Intervention: Desmethylselegiline
Number of subjects: 8
Study 8584010 — intervention group
Group type: EXPERIMENTAL
Intervention: Mid-term placenta from GDM patients
Number of subjects: 0
Study 8584010 — intervention group
Group type: EXPERIMENTAL
Intervention: Full-term placenta from GDM patients
Number of subjects: 0
Study 8584010 — intervention group
Group type: COMPARATOR
Intervention: Mid-term placenta from normal pregnant women (N)
Number of subjects: 0
Study 8584010 — intervention group
Group type: EXPERIMENTAL
Intervention: Placental membrane protein content in GDM
Number of subjects: 0
Study 8584010 — intervention group
Group type: EXPERIMENTAL
Intervention: Competitive binding assay in GDM patients
Number of subjects: 0
Study 8584010 — intervention group
Group type: COMPARATOR
Intervention: Competitive binding assay in normal pregnant women (N)
Number of subjects: 0
Study 2601986 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxybutynin chloride and verapamil combination
Number of subjects: 14
Study 2601986 — intervention group
Group type: COMPARATOR
Intervention: Verapamil alone
Number of subjects: 14
Study 2601986 — intervention group
Group type: COMPARATOR
Intervention: Oxybutynin chloride alone
Number of subjects: 14
Study 778564 — intervention group
Group type: EXPERIMENTAL
Intervention: Gaviscon (alginate/alginic acid plus antacid)
Number of subjects: 20
Study 778564 — intervention group
Group type: COMPARATOR
Intervention: Standard antacid
Number of subjects: 20
Study 30404676 — intervention group
Group type: EXPERIMENTAL
Intervention: Square‐stepping Exercise (SSE) 2x/week for 24 weeks
Number of subjects: 0
Study 30404676 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 28489641 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane General Anesthesia (GA)
Number of subjects: 722
Study 28489641 — intervention group
Group type: COMPARATOR
Intervention: Bupivacaine Regional Anesthesia (RA)
Number of subjects: 722
Study 26603973 — intervention group
Group type: EXPERIMENTAL
Intervention: Lurasidone
Number of subjects: 0
Study 23152490 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduced model with 12 factors (concordance probability estimate, 0.693)
Number of subjects: 6975
Study 23152490 — intervention group
Group type: EXPERIMENTAL
Intervention: Full final model with 25 predictors (concordance probability estimate, 0.70)
Number of subjects: 6975
Study 23152490 — intervention group
Group type: EXPERIMENTAL
Intervention: Subgroup analysis of biomarkers (high-sensitivity cardiac troponin T and N-terminal pro-brain natriuretic peptide)
Number of subjects: 6975
Study 21610356 — intervention group
Group type: EXPERIMENTAL
Intervention: Low mean arterial pressure (LMAP) strategy with target MAP of 50 mm Hg
Number of subjects: 90
Study 21610356 — intervention group
Group type: COMPARATOR
Intervention: High mean arterial pressure (HMAP) strategy with standard fluid resuscitation to a target MAP of 65 mm Hg
Number of subjects: 90
Study 19390963 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-week psycho-educational group intervention
Number of subjects: 411
Study 19390963 — intervention group
Group type: COMPARATOR
Intervention: Control condition (print material only)
Number of subjects: 411
Study 17145854 — intervention group
Group type: EXPERIMENTAL
Intervention: HPV16 L2E7E6 vaccine (533-mug) administered thrice at monthly intervals to healthy volunteers
Number of subjects: 69
Study 12843005 — intervention group
Group type: EXPERIMENTAL
Intervention: Binax NOW S. pneumoniae urinary antigen test
Number of subjects: 107
Study 11310378 — intervention group
Group type: EXPERIMENTAL
Intervention: L-carnitine (2 g/day for 3 months)
Number of subjects: 47
Study 11310378 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 47
Study 8878600 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral ofloxacin (7.5 mg.kg of body weight‐1 given over 30 min)
Number of subjects: 17
Study 8878600 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous ofloxacin (7.5 mg.kg of body weight‐1)
Number of subjects: 17
Study 8878600 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral ofloxacin
Number of subjects: 17
Study 8878600 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous and oral ofloxacin
Number of subjects: 17
Study 1725032 — intervention group
Group type: EXPERIMENTAL
Intervention: Ramipril monotherapy (1.25-10 mg/day)
Number of subjects: 105
Study 1725032 — intervention group
Group type: EXPERIMENTAL
Intervention: Ramipril (5 mg/day) plus piretanide (3 mg/day)
Number of subjects: 105
Study 1725032 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril (100 mg/day)
Number of subjects: 105
Study 1725032 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril (10-20 mg/day)
Number of subjects: 105
Study 1725032 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide (50 mg/day)
Number of subjects: 105
Study 1725032 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol (100 mg/day)
Number of subjects: 105
Study 6338905 — intervention group
Group type: EXPERIMENTAL
Intervention: Timolol 0.25%
Number of subjects: 0
Study 6338905 — intervention group
Group type: COMPARATOR
Intervention: Timolol 0.5%
Number of subjects: 0
Study 29945801 — intervention group
Group type: EXPERIMENTAL
Intervention: DMEK
Number of subjects: 38
Study 29945801 — intervention group
Group type: COMPARATOR
Intervention: UT‐DSAEK
Number of subjects: 38
Study 31097284 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-oral (IO) bone graft harvesting
Number of subjects: 23
Study 31097284 — intervention group
Group type: COMPARATOR
Intervention: Extra-oral (EO) bone graft harvesting
Number of subjects: 23
Study 26813209 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily 4000 IU vitamin D plus a prenatal vitamin containing 400 IU vitamin D
Number of subjects: 876
Study 26813209 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus a prenatal vitamin containing 400 IU vitamin D
Number of subjects: 876
Study 24297848 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise intervention in sedentary, overweight/obese individuals
Number of subjects: 0
Study 24297848 — intervention group
Group type: EXPERIMENTAL
Intervention: T2D-derived myotubes
Number of subjects: 0
Study 24297848 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucose and palmitate in vitro
Number of subjects: 0
Study 24297848 — intervention group
Group type: EXPERIMENTAL
Intervention: Circulating irisin
Number of subjects: 0
Study 24297848 — intervention group
Group type: EXPERIMENTAL
Intervention: Fndc5 in adipose tissue and irisin in plasma
Number of subjects: 0
Study 22337680 — intervention group
Group type: EXPERIMENTAL
Intervention: Amoxicillin (1500 mg/d for 10 days)
Number of subjects: 166
Study 22337680 — intervention group
Group type: COMPARATOR
Intervention: Placebo (10 days)
Number of subjects: 166
Study 20664229 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute tryptophan depletion (ATD)
Number of subjects: 0
Study 20664229 — intervention group
Group type: COMPARATOR
Intervention: Taste-matched placebo
Number of subjects: 0
Study 17906193 — intervention group
Group type: EXPERIMENTAL
Intervention: EGCG (Teavigo) 150 mg capsule twice daily
Number of subjects: 38
Study 17906193 — intervention group
Group type: COMPARATOR
Intervention: Placebo (lactose)
Number of subjects: 38
Study 15723896 — intervention group
Group type: EXPERIMENTAL
Intervention: Disclosure group (n = 19)
Number of subjects: 34
Study 15723896 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 15)
Number of subjects: 34
Study 12184147 — intervention group
Group type: EXPERIMENTAL
Intervention: Olein Group (OG) - 100% olein
Number of subjects: 60
Study 12184147 — intervention group
Group type: EXPERIMENTAL
Intervention: Mix Group (MG) - 50% olein
Number of subjects: 60
Study 12184147 — intervention group
Group type: COMPARATOR
Intervention: Control Group (CG) - regular fats
Number of subjects: 60
Study 9542187 — intervention group
Group type: EXPERIMENTAL
Intervention: ITT
Number of subjects: 80
Study 9542187 — intervention group
Group type: EXPERIMENTAL
Intervention: Sidefocus Technique
Number of subjects: 80
Study 9542187 — intervention group
Group type: COMPARATOR
Intervention: Incision
Number of subjects: 80
Study 9542187 — intervention group
Group type: COMPARATOR
Intervention: TURP
Number of subjects: 80
Study 9542187 — intervention group
Group type: COMPARATOR
Intervention: TURP and Incision
Number of subjects: 80
Study 9542187 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser Techniques (ITT and Sidefocus)
Number of subjects: 80
Study 7845546 — intervention group
Group type: COMPARATOR
Intervention: Atenolol (100 mg)
Number of subjects: 16
Study 7845546 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol plus melatonin (1 mg at 19.30 h and 0.75 mg at 21.00 and 23.00 h)
Number of subjects: 16
Study 3385910 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral methylprednisolone (160 or 320 mg daily)
Number of subjects: 77
Study 3385910 — intervention group
Group type: COMPARATOR
Intervention: Intravenous methylprednisolone (500 or 1000 mg daily)
Number of subjects: 77
Study 31731093 — intervention group
Group type: EXPERIMENTAL
Intervention: Training program for partial automation system
Number of subjects: 0
Study 31731093 — intervention group
Group type: COMPARATOR
Intervention: Untrained drivers
Number of subjects: 0
Study 30520317 — intervention group
Group type: EXPERIMENTAL
Intervention: Uncemented HA-coated femoral stem
Number of subjects: 26
Study 30520317 — intervention group
Group type: COMPARATOR
Intervention: Cemented femoral stem
Number of subjects: 26
Study 28701493 — intervention group
Group type: EXPERIMENTAL
Intervention: Creatine (40 g daily for up to 48 months)
Number of subjects: 553
Study 28701493 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 553
Study 28701493 — intervention group
Group type: EXPERIMENTAL
Intervention: Creatine
Number of subjects: 553
Study 26372412 — intervention group
Group type: EXPERIMENTAL
Intervention: Buprenorphine (20 μg/h) transdermal patch
Number of subjects: 22
Study 26372412 — intervention group
Group type: COMPARATOR
Intervention: Placebo transdermal patch
Number of subjects: 22
Study 23141049 — intervention group
Group type: EXPERIMENTAL
Intervention: 1/3D-1 yr
Number of subjects: 1355
Study 23141049 — intervention group
Group type: EXPERIMENTAL
Intervention: FD-3 yr
Number of subjects: 1355
Study 23141049 — intervention group
Group type: COMPARATOR
Intervention: FD-1 yr
Number of subjects: 1355
Study 23141049 — intervention group
Group type: COMPARATOR
Intervention: 1/3D
Number of subjects: 1355
Study 23141049 — intervention group
Group type: COMPARATOR
Intervention: FD
Number of subjects: 1355
Study 23141049 — intervention group
Group type: EXPERIMENTAL
Intervention: 1/3D-3 yr
Number of subjects: 1355
Study 22024058 — intervention group
Group type: EXPERIMENTAL
Intervention: Da-Cheng-Qi-Tang (DCQT)
Number of subjects: 69
Study 19190928 — intervention group
Group type: EXPERIMENTAL
Intervention: 600 microg powdery sublingual misoprostol
Number of subjects: 54
Study 19190928 — intervention group
Group type: COMPARATOR
Intervention: 600 microg sublingual misoprostol tablet
Number of subjects: 54
Study 17196475 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin 325 mg/day for 4 days
Number of subjects: 10
Study 17196475 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine 150 mg twice daily for 3 days
Number of subjects: 10
Study 17196475 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of aspirin and ranitidine
Number of subjects: 10
Study 17196475 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin with ranitidine
Number of subjects: 10
Study 15273579 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced counseling
Number of subjects: 4328
Study 15273579 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief counseling
Number of subjects: 4328
Study 15273579 — intervention group
Group type: COMPARATOR
Intervention: Educational messages
Number of subjects: 4328
Study 11305769 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized management plus cerebral decompression (decompressive bitemporal craniectomy performed at a median of 19.2 h after injury)
Number of subjects: 27
Study 11305769 — intervention group
Group type: COMPARATOR
Intervention: Standardized management alone (control group)
Number of subjects: 27
Study 9387942 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide 200 microg b.i.d. for 12 months
Number of subjects: 75
Study 9387942 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 75
Study 7636948 — intervention group
Group type: EXPERIMENTAL
Intervention: Milk-fed group
Number of subjects: 45
Study 7636948 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% glucose, water-fed group
Number of subjects: 45
Study 7636948 — intervention group
Group type: COMPARATOR
Intervention: Control (preprandial baseline)
Number of subjects: 45
Study 7636948 — intervention group
Group type: COMPARATOR
Intervention: Celiac artery
Number of subjects: 45
Study 3233185 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical administration of RA gel
Number of subjects: 41
Study 3233185 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 41
Study 2129513 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic walking training requiring 90-100% HR of the AT level for 30 min, four to six days per week
Number of subjects: 27
Study 2129513 — intervention group
Group type: COMPARATOR
Intervention: Control group (no aerobic training)
Number of subjects: 27
Study 4564378 — intervention group
Group type: EXPERIMENTAL
Intervention: Tolbutamide
Number of subjects: 0
Study 30738980 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac Resynchronization Therapy (CRT)
Number of subjects: 614
Study 30738980 — intervention group
Group type: EXPERIMENTAL
Intervention: CRT-P
Number of subjects: 614
Study 30738980 — intervention group
Group type: EXPERIMENTAL
Intervention: CRT-D
Number of subjects: 614
Study 30738980 — intervention group
Group type: COMPARATOR
Intervention: Optimal Pharmacologic Therapy (OPT)
Number of subjects: 614
Study 28481883 — intervention group
Group type: EXPERIMENTAL
Intervention: TV003 vaccine (live attenuated tetravalent dengue vaccine)
Number of subjects: 58
Study 25858003 — intervention group
Group type: EXPERIMENTAL
Intervention: valsartan 80 mg/daily
Number of subjects: 100
Study 25858003 — intervention group
Group type: EXPERIMENTAL
Intervention: valsartan 160 mg/daily
Number of subjects: 100
Study 25858003 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 100
Study 24108316 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D₃ 4000 IU/d
Number of subjects: 21
Study 24108316 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study 21521683 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (group D)
Number of subjects: 72
Study 21521683 — intervention group
Group type: COMPARATOR
Intervention: Routine sedative protocol (Midazolam and fentanyl) (group M)
Number of subjects: 72
Study 19549033 — intervention group
Group type: EXPERIMENTAL
Intervention: Maximum voltage-guided (MVG) technique
Number of subjects: 69
Study 19549033 — intervention group
Group type: COMPARATOR
Intervention: Anatomical approach
Number of subjects: 69
Study 17938318 — intervention group
Group type: EXPERIMENTAL
Intervention: Adenotonsillectomy (ATY)
Number of subjects: 300
Study 17938318 — intervention group
Group type: COMPARATOR
Intervention: Watchful waiting
Number of subjects: 300
Study 15029143 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril (37.5‐150 mg, average dose 72+/‐34.2 mg/day)
Number of subjects: 66
Study 15029143 — intervention group
Group type: EXPERIMENTAL
Intervention: Eprosartan (300‐600 mg, average dose 471+/‐151 mg/day)
Number of subjects: 66
Study 15029143 — intervention group
Group type: COMPARATOR
Intervention: Captopril
Number of subjects: 66
Study 15029143 — intervention group
Group type: COMPARATOR
Intervention: Eprosartan
Number of subjects: 66
Study 15029143 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 66
Study 11775049 — intervention group
Group type: EXPERIMENTAL
Intervention: Venlafaxine XR
Number of subjects: 2021
Study 11775049 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2021
Study 9770742 — intervention group
Group type: EXPERIMENTAL
Intervention: Optimal pedalling rate (OPR) 60 rpm
Number of subjects: 124
Study 9770742 — intervention group
Group type: EXPERIMENTAL
Intervention: Muscular load chosen by the patient (regimen 2)
Number of subjects: 124
Study 9770742 — intervention group
Group type: EXPERIMENTAL
Intervention: Free-choice daily load (regimen 3)
Number of subjects: 124
Study 9770742 — intervention group
Group type: EXPERIMENTAL
Intervention: Optimal pedalling rate (OPR) 30 and 45 rpm
Number of subjects: 124
Study 7936300 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-aminopyridine (4-AP)
Number of subjects: 20
Study 7936300 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 2457043 — intervention group
Group type: EXPERIMENTAL
Intervention: Imipenem
Number of subjects: 40
Study 2457043 — intervention group
Group type: COMPARATOR
Intervention: Penicillin
Number of subjects: 40
Study 29601270 — intervention group
Group type: EXPERIMENTAL
Intervention: Goal-setting text message reminders
Number of subjects: 50
Study 29601270 — intervention group
Group type: COMPARATOR
Intervention: Generic text message reminders
Number of subjects: 50
Study 27165052 — intervention group
Group type: COMPARATOR
Intervention: List of wishes/statements (LOS)
Number of subjects: 100
Study 27165052 — intervention group
Group type: EXPERIMENTAL
Intervention: Go Wish card game (GWG)
Number of subjects: 100
Study 24462657 — intervention group
Group type: EXPERIMENTAL
Intervention: Echocardiography-guided (EG) left ventricular lead placement
Number of subjects: 183
Study 24462657 — intervention group
Group type: COMPARATOR
Intervention: Routine strategy for left ventricular lead placement
Number of subjects: 183